
Fig. 1


anti-PD-1 antibody
PD-1
PD-L1
cancer cell
T cell
HLA
TCR
cancer antigen
anti-CTLA-4 antibody
CTLA-4
B7
CD28
dendritic cell
T cell
HLA
TCR
cancer antigen

5

Fig. 2



Wnt
Recepter
Mutation
β-Catenin
CANCER CELL
β-Catenin
CBP
TCF
NUCLEUS
DNA
Proliferation
Wnt
Recepter
Mutation
β-Catenin
CANCER CELL
β-Catenin
P300
TCF
NUCLEUS
CBP
PRI-724
Differentiation

Fig. 3



Vehicle
1.6%
Hoechst Blue-A
Hoechst Red-A
0
200
400
600
800
1K
compound 2 (active metabolite of compound 1)
@ 0.3µM
0.0%
Cell: MDA-MB-231
Time point: 96h

Fig. 4




Tumor growth - compound 1 @80mpk
(CT26)
1500
1000
500
0
Tumor volume (mm3)
Vehicle
PD-L1@2mpk
compound 1 @80mpk
compound 1
@80mpk+PD-L1@2mpk**
0
3
6
9
12
15
Days post administration
**, p<0.01; repeated measurement Two-Way ANOVA.

Fig. 5


IL-10_24hr
200
180
160
140
120
100
80
60
40
20
0
pg/ml
624
928
0 uM
0.2 uM
1 uM